uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Acute coronary syndrome: the present and future role of biomarkers
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology.
2013 (English)In: Clinical Chemistry and Laboratory Medicine, ISSN 1434-6621, Vol. 51, no 9, 1699-1706 p.Article, review/survey (Refereed) Published
Abstract [en]

Over the past two decades there have been dramatic changes in the diagnosis, treatment and prognosis of acute coronary syndrome (ACS). Several new treatment modalities have been added and the prognosis has improved dramatically. Biomarkers play a crucial role in the management of ACS. At present, cardiac troponin is the biomarker of choice for diagnosis of acute myocardial infarction (AMI). Currently, there are no other biomarkers, which can compete, neither regarding specificity nor regarding early sensitivity. However, there is still a clinical need of a biomarker able to reliably rule-in or rule-out AMI immediately on admission. MicroRNAs seem to be promising new candidates for diagnostic purposes. The optimal combination of biomarkers and new imaging techniques is another important area for research. The list of biomarkers associated with an adverse prognosis in ACS is long. However, for most of them it has been very difficult to prove an added clinical value. Only cardiac troponin, and to some degree also B-type natriuretic peptides, is widely used in clinical practice for risk assessment. Among new markers, growth differentiation factor 15 and the mid-regional part of the prohormone of adrenomedullin, have shown some promising results. Since the renal function is assessed in clinical routine, also markers of the renal function have gained increasing interest. Cardiac troponin has been proven useful for selection of antithrombotic, antiplatelet and invasive treatment. Besides cardiac troponin, no other markers have consistently been shown to be useful for selection of specific treatments.

Place, publisher, year, edition, pages
2013. Vol. 51, no 9, 1699-1706 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-205086DOI: 10.1515/cclm-2013-0074ISI: 000324177500012PubMedID: 23525876OAI: oai:DiVA.org:uu-205086DiVA: diva2:640534
Available from: 2013-08-13 Created: 2013-08-13 Last updated: 2013-10-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindahl, Bertil
By organisation
UCR-Uppsala Clinical Research CenterCardiology
In the same journal
Clinical Chemistry and Laboratory Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 157 hits
ReferencesLink to record
Permanent link

Direct link